Activity- and schedule-dependent interactions of paclitaxel, etoposide and hydroperoxy-ifosfamide in cisplatin-sensitive and -refractory human ovarian carcinoma cell lines.

por Klaassen, U., Harstrick, A., Schleucher, N., Vanhoefer, U., Schröder, J., Wilke, H., Seeber, S.
Publicado 1996

Grundlagen der systemischen Therapie

por Doehn, C., Huland, E., Jäger, T., Jocham, D., Krege, S., Rübben, H., Schleucher, N., Seeber, S., Vanhoefer, U.
Publicado 2007

Treatment-induced anaemia and its potential clinical impact in patients receiving sequential high dose chemotherapy for metastatic testicular cancer

por Bokemeyer, C, Oechsle, K, Hartmann, J T, Schöffski, P, Schleucher, N, Metzner, B, Schleicher, J, Kanz, L
Publicado 2002

Reversal of MDR1-associated resistance to topotecan by PAK-200S, a new dihydropyridine analogue, in human cancer cell lines

por Vanhoefer, U, Müller, M R, Hilger, R A, Lindtner, B, Klaassen, U, Schleucher, N, Rustum, Y M, Seeber, S
Publicado 1999

First-line sequential high-dose VIP chemotherapy with autologous transplantation for patients with primary mediastinal nonseminomatous germ cell tumours: a prospective trial

por Bokemeyer, C, Schleucher, N, Metzner, B, Thomas, M, Rick, O, Schmoll, H-J, Kollmannsberger, C, Boehlke, I, Kanz, L, Hartmann, J T
Publicado 2003